Skip to main content

Table 1 population characteristics

From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Characteristics Number of patients Percentage & range P (Cox analysis for PFS)
Gender 56 100% 0.050
 Male 33 58.9%  
 Female 23 41.1%  
Age at diagnosis 0.982
 Median (min–max) (year) 24.5 9–63  
Pathological diagnosis 56 100% 0.087
 Osteosarcoma 22 39.3%  
 Ewing sarcoma 10 17.9%  
 Synovial sarcoma 6 10.7%  
 MPNSTa 3 5.4%  
 Epithelioid sarcoma 2 3.6%  
 UPSb 4 7.1%  
 Fibrosarcoma 1 1.8%  
 Chondrosarcoma 3 5.4%  
 ASPSc 3 5.4%  
 Othersd 2 3.6%  
Tumor grade
 Grade III 56 100%  
Location of primary disease 56 100% 0.374
 Axial skeleton 17 30.3%  
 Extremities 37 66.1%  
 Otherse 2 3.6%  
Localization of relapse 56 100% 0.541
 Localized 3 5.6%  
 Metastatic 41 73.2%  
 Both 12 21.4%  
Type of metastasis 53 94.6% 0.197
 Lung only 40 71.4%  
 Bone only 3 5.4%  
 Both 5 8.9%  
 Othere 5 8.9%  
Time interval from initial chemotherapy to using apatinib 0.584
 Median (min–max) (month) 15.6 0.9–373.9  
Number of previous treatment lines 56 100% 0.231
 0 5 8.9%  
 1 37 66.1%  
 2 12 21.4%  
  > 2 2 3.6%  
Follow-up time
 Median (min–max) (month) 6.0 0.7–18.0  
  1. aMPNST: malignant peripheral nerve sheath tumor
  2. bUPS: undifferentiated pleomorphic sarcoma
  3. cASPS: alveolar soft part sarcoma
  4. dothers including extraskeletal osteosarcoma one case and mucinous type liposarcoma one case
  5. eothers including mediastinum and soft tissue of the backside
  6. fothers including lymph nodes metastasis or intravenous tumor emboli as well as liver, brain metastasis